DENVER, Nov. 2 /PRNewswire-FirstCall/ -- Accelr8 Technology Corp. today reported that product sales nearly tripled to $336,610 for OptiChem(TM) microarraying slides for the fiscal year ending July 31, 2005. Overall performance resulted in a net loss of $2,090,800 or $0.21 per share over the same period. For the prior fiscal year ended July 31, 2004 the company had reported a net loss $909,421 or $0.09 per share after a one-time gain from sale of discontinued operations of $621,191 and income from discontinued operations of $168,210.
“In 2005, we continued our aggressive development of the BACcelr8r(TM) rapid bacterial analysis system, which remains on track to set new standards in clinical microbiology,” said David Howson, president. “We’ve installed our first in-house research version of the BACcelr8r, and are using its higher throughput to accelerate our microbiology program. We also started the engineering design on the next generation of research platform. At the same time, the growing sales of microarray products indicates increasing industry acceptance as the market matures toward molecular diagnostics.”
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. In addition to its microarraying products, Accelr8 is also developing a rapid clinical pathogen platform, the BACcelr8r(TM), based on its innovative surface coatings, assay processing, and detection technologies.
Accelr8 Technology Corp.
CONTACT: John Metzger of Metzger Associates, +1-303-786-7000, ext. 2202,john@metzger.com, for Accelr8 Technology; or David Howson of Accelr8Technology, +1-303-863-8088, david.howson@accelr8.com
Web site: http://www.accelr8.com/
